Insilicos, a Seattle, Wash.-based biomedical software firm, announced this week that Ruedi Aebersold has joined its scientific advisory board. Aebersold is currently a professor of systems biology at the Swiss Federal Institute of Technology in Zurich.
Xceleron announced this week the appointment of J. Scott Tarrant as vice president of business development for North America. In his new position, Tarrant will be responsible for the commercialization of Xceleron’s accelerator mass spectrometry technology.
Prior to joining Xceleron, Tarrant led a sales team for both genomics and preclinical contract research organization services at Gene Logic.
Millipore announced last week that its new president and CEO, Martin Madaus, will start on Jan. 1, 2005. He will also join Millipore’s board of directors at that time. Madaus is assuming the roles of president and CEO from Francis Lunger, who will remain as chairman of the board until March 1, 2005, Millipore said.
In connection with its integration with Inveresk Research Group, Charles River Laboratories has promoted Nancy Gillet to the post of senior vice president and president of global preclinical services for. Gillet succeeds Michael Ankcorn, who is retiring from the firm effective Dec. 31. She previously served as corporate vice president and president of US preclinical services.
In addition, Charles River announced that Glenn Kerkhof was named interim president of global clinical services, succeeding Alistair McEwan, who left the company last week. Paul Oskar was promoted to general manager and president of US preclinical services from his previous position as general manager, DDS Worcester division. Christopher Perkin, the firm’s current chief operating officer of CTBR, was named general manager and president of Canadian preclinical services.